

Philadelphia Immunization Program

Immunization Update



Department of
Public Health
CITY OF PHILADELPHIA
LIFE • LIBERTY • AND YOU™

June 30, 2015

New 9-valent HPV Vaccine

Beginning July 1, 2015, the Philadelphia Vaccines For Children (VFC) Program will cutover entirely to supplying the recently licensed recommended 9-valent human papillomavirus (9vHPV) GARDASIL®9 vaccine to replace the currently supplied 4-valent human papillomavirus (4vHPV) GARDASIL®4 vaccine. Both vaccines are manufactured by Merck, Sharpe and Dohme Corp.

Recommendations for Use of HPV Vaccines for VFC-eligible Children

The Advisory Committee on Immunization Practices (ACIP) recommends that routine HPV vaccination be initiated at age 11 or 12 years. The vaccination series can be started beginning at age 9 years in high-risk cases. Vaccination is also recommended for females and males aged 13 through 18 years who have not been vaccinated previously, or who have not completed the 3-dose HPV series. Vaccination with 4vHPV is recommended for those already initiated with 1 or 2 doses of 4vHPV. If this formulation is unavailable, 9vHPV should be substituted to complete the series on schedule. Vaccination of immunologically naïve females and males is recommended with 9vHPV or - if unavailable – 4vHPV. Do not delay initiating HPV vaccination awaiting 9vHPV supply.

All currently marketed HPV vaccines protect against HPV types 16 and 18 that cause about 66% of cervical cancers and the majority of other HPV-attributable cancers in the United States. 9vHPV targets five additional cancer-causing types, which account for about 15% of cervical cancers. 4vHPV and 9vHPV also protect against HPV 6 and 11, types that cause anogenital warts.

Administration of HPV Vaccines

4vHPV and 9vHPV are each administered in a 3-dose schedule. The second dose is administered at least 1 to 2 months after the first dose and the third dose at least 6 months after the first dose. If the vaccine schedule is interrupted, the vaccination series does not need to be restarted.

If vaccination providers do not know or do not have available the HPV vaccine type previously administered, 9vHPV vaccine may be used to continue or complete the 3-dose HPV series for females and males.

9vHPV CVX Code: 165

9vHPV CPT Code: 90651